Provided by Tiger Fintech (Singapore) Pte. Ltd.

Denali Therapeutics Inc.

11.78
-1.0100-7.90%
Post-market: 11.780.00000.00%19:25 EDT
Volume:1.53M
Turnover:18.05M
Market Cap:1.71B
PE:-4.58
High:12.63
Open:12.32
Low:11.33
Close:12.79
Loading ...

DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up

Zacks
·
03 Apr

BUZZ-Denali Therapeutics begins marketing application for genetic disorder drug, shares rise

Reuters
·
02 Apr

Denali Therapeutics Files Application for Accelerated Approval of Hunter Syndrome Treatment; Shares Up

MT Newswires Live
·
02 Apr

Denali initiates BLA filing for accelerated approval of tividenofusp alfa

TIPRANKS
·
02 Apr

BRIEF-Denali Therapeutics Announces Initiation Of BLA Filing For Accelerated Approval Of Tividenofusp Alfa For Treatment Of Hunter Syndrome

Reuters
·
02 Apr

Denali Therapeutics Announces Initiation of Bla Filing for Accelerated Approval of Tividenofusp Alfa for Treatment of Hunter Syndrome (Mps Ii) and Positive Ongoing Interactions With FDA on Dnl126 Through Start Program

THOMSON REUTERS
·
02 Apr

Denali Therapeutics : Expects to Complete Bla Submission in First Half of May 2025

THOMSON REUTERS
·
02 Apr

Denali Therapeutics Inc: Continues to Prepare for a Potential Commercial Launch in U.S. in Late 2025 or Early 2026

THOMSON REUTERS
·
02 Apr

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

GlobeNewswire
·
02 Apr

Biotech stocks have been hit by 'DOGE' and other fears. Why they're a great value now.

Dow Jones
·
27 Mar

Why You Shouldn't Bet Against Denali (DNLI) Stock

Zacks
·
20 Mar

Denali Therapeutics Coverage Assumed by Morgan Stanley at Overweight

Dow Jones
·
08 Mar

Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI), Disc Medicine (IRON) and PTC Therapeutics (PTCT)

TIPRANKS
·
07 Mar

BRIEF-Denali Therapeutics Inc To Discontinue Active Treatment Extension In Regimen G

Reuters
·
06 Mar

Denali Therapeutics discontinues active treatment extension in eIF2B Regimen G

TIPRANKS
·
06 Mar

Denali Therapeutics Inc - to Discontinue Active Treatment Extension in Regimen G

THOMSON REUTERS
·
06 Mar

B. Riley Trims Price Target on Denali Therapeutics to $35 From $38, Keeps Buy Rating

MT Newswires Live
·
05 Mar

Stock Track | Denali Therapeutics Inc. (DNLI) Soars 5.33% in Pre-Market Trading on Positive Analyst Insights

Stock Track
·
05 Mar

Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI), Ardent Health Partners, Inc. (ARDT) and Doximity (DOCS)

TIPRANKS
·
05 Mar

Stock Track | Denali Therapeutics Plummets 5.16% as Price Target Cut on Lowered Probability of Success

Stock Track
·
04 Mar